While venture capital funding for biotechnology reached a robust $9.1B in the first half of 2026, the highest first-half total since 2022, a stark divide has emerged between late-stage firms and early-stage startups. Driven by strong IPO performance and a record-setting M&A pace, 76% of capital raised was concentrated in "megarounds" of $100M or more. Crucially, two-thirds of these deals went to companies already conducting human clinical trials.

This trend highlights a widening funding gap for seed-stage startups and first-time founders, who are finding capital increasingly scarce compared to five years ago. Analysts warn that this shift, compounded by broader cuts to basic research funding, threatens the long-term "pipeline" of early innovation. Investors are currently prioritizing de-risked assets, often turning toward startups built around ready-made clinical prospects. While the sector remains liquid, the investment climate has become highly discerning, favoring proven management teams and advanced platforms over nascent research ventures.

Across more than 20 years of the Prix Galien USA Awards, just 11 vaccine breakthroughs have been recognized. Compare that with 89 awards for therapeutic drugs—medicines designed to treat disease rather than prevent it.

That said, the landscape appears to be shifting. Recognition for vaccine innovation has accelerated in the years following the COVID-19 pandemic, reflecting a renewed appreciation for the impact vaccines can have on global health.

The data raises an interesting question:

Has the industry historically undervalued preventive medicine, or is this simply a reflection of where the greatest scientific breakthroughs have occurred?

Follow The Galien Foundation on LinkedIn to stay updated on announcements, speakers, and innovations and upcoming event.

In a significant move for the life sciences sector, the UK government has finalized a trade agreement with Switzerland that explicitly codifies intellectual property (IP) protections for pharmaceuticals, the first instance of such provisions being integrated into a free trade agreement. The deal secures the current "eight plus two" year regulatory data protection (RDP) framework, consisting of eight years of data exclusivity and 10 years of market exclusivity, alongside five-year patent term extensions for regulatory delays. By "locking in" these standards, both nations aim to provide long-term stability and regulatory confidence for innovative companies planning R&D investments. While industry leaders like the ABPI, Roche, and AstraZeneca have lauded the agreement as a vital step for fostering a pro-innovation environment, the deal faces scrutiny from patient advocacy groups who caution that restricting the entry of low-cost generics could place upward pressure on NHS medicine expenditures.

Insilico Medicine has entered a strategic partnership with the contract development and manufacturing organization (CDMO) Bora Pharmaceuticals, a deal valued at up to $2.5B. This collaboration represents the latest in a series of high-profile agreements for Insilico, building on recent partnerships with industry leaders such as Eli Lilly, Servier, Takeda, and SK Biosciences.

The alliance integrates Insilico’s proprietary Pharma.AI platform, which covers target discovery, generative chemistry, and molecule optimization, with Bora’s extensive development and manufacturing capabilities. The objective is to establish an "integrated pathway" that bridges the gap between AI-driven discovery and commercial production. For Bora, the deal also serves as a catalyst for internal digital transformation, aiming to enhance "AI literacy" across its supply chain and distribution operations. Insilico continues to demonstrate the efficiency of its platform, having nominated 31 preclinical candidates since 2021, with 13 securing IND approvals, frequently accelerating development timelines to nearly half the industry standard.

The landscape of drug discovery is undergoing a fundamental transformation as multi-billion-dollar investments pivot from single-asset programs toward "AI-native" infrastructure. Industry leaders, including Isomorphic Labs, are moving away from traditional, target-specific discovery models to build general-purpose design engines capable of tackling previously intractable biological challenges.

Platforms like Isomorphic’s IsoDD are expanding the druggable landscape by probing previously inaccessible biology, such as "cryptic" binding pockets and induced-fit interactions. Meanwhile, a wave of major partnerships, involving giants like Pfizer, Eli Lilly, and Incyte, is fueling the training of foundation models with proprietary datasets. Investors are prioritizing startups that demonstrate measurable improvements in the drug discovery process, such as those modeling sequence-based medicines or predictive ADMET platforms. While few AI-designed drugs have reached the clinic, analysts argue that now is the vital window for innovation, as those who integrate these generative design workflows today will define the future of therapeutic development.